News | August 19, 2024
Zydus Lifesciences to scale up US specialties business
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
EBITDA at Rs. 250 crore, up 47% YoY, with 35% EBITDA margin
Ursodeoxycholic acid or ursodiol is a naturally occurring bile acid that is used dissolve cholesterol gall stones
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
The Unit has been issued GMP Certification from ANVISA-Brazil
This plant is located at Baddi, Himachal Pradesh spread over an area of 2.85 acres
The company has reported total income of Rs. 155.79 crores during the period ended March 31, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
USFDA inspects Zydus Lifesciences’ Ahmedabad SEZ Onco manufacturing plant
Subscribe To Our Newsletter & Stay Updated
